Enrofloxacin 5 mg/ML / silver sulfadiazine 10 mg/ML [Baytril Otic]
RxNorm 894770

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 894770 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: enrofloxacin 5 mg/ML / silver sulfadiazine 10 mg/ML [Baytril Otic].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Enrofloxacin 5 mg/ML / silver sulfadiazine 10 mg/ML [Baytril Otic]
AUI:7234555
View
TMSY
Enrofloxacin 5 mg/ML / silver sulfADIAZINE 10 mg/ML [Baytril Otic]
AUI:7235586
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDC

Semantic Branded Drug Component (SBDC):
Enrofloxacin 5 mg/ML / silver sulfadiazine 10 mg/ML [Baytril Otic]
(Atom ID: 7234555)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
enrofloxacin 5 MG/ML / silver sulfadiazine 10 MG/ML [Baytril Otic]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
894770
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
7234555
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
894770
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
TMSY

Tall Man Lettering Synonym (TMSY):
Enrofloxacin 5 mg/ML / silver sulfADIAZINE 10 mg/ML [Baytril Otic]
(Atom ID: 7235586)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
enrofloxacin 5 MG/ML / silver sulfADIAZINE 10 MG/ML [Baytril Otic]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
894770
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
7235586
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
TMSY
Tall Man Lettering Synonym (Tall Man Lettering synonym of another TTY, given to distinguish between commonly confused drugs.)
Source Code
894770
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.